Bringing Neuroplastogens to the Window: Q&A With Delix CEO Mark Rus

Rus discusses his company’s work with neuroplastogens and how they differ from similar, psychedelic treatments.

admin

Leave a Reply

Your email address will not be published. Required fields are marked *

Powered by WordPress | WP Newspaper by WP Mag Plus